Dare Bioscience, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Dare Bioscience, Inc. (DARE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $286.60 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $286.60K, a 20.17% decline year-over-year.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $455.06K, a 20.59% increase year-over-year.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $403.03K, a 23.02% decline year-over-year.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $359.02K, a 36.20% decline year-over-year.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.50M, a 32.08% decline from fiscal 2024.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.20M, a 12.94% decline from fiscal 2023.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.53M, a 17.24% increase from fiscal 2022.
- Dare Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.16M, a 34.93% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $286.60K 10-Q · filed 2026-08-13 | $741.67K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $455.06K 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $1.50M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $403.03K 10-Q · filed 2025-11-13 | $762.04K derived: sum of 2 quarters · filed 2026-08-13 | $1.14M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $359.02K 10-Q · filed 2026-08-13 | $736.38K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $377.36K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $2.20M 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $523.58K 10-Q · filed 2025-11-13 | $1.09M derived: sum of 2 quarters · filed 2025-11-13 | $1.71M derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $562.72K 10-Q · filed 2025-11-13 | $1.19M derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $627.70K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $2.53M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $636.09K 10-Q · filed 2024-11-14 | $1.29M derived: sum of 2 quarters · filed 2024-11-14 | $1.91M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $650.19K 10-Q · filed 2024-11-14 | $1.27M derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $624.62K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $2.16M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $556.45K 10-Q · filed 2023-11-09 | $1.09M derived: sum of 2 quarters · filed 2023-11-09 | $1.63M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $537.52K 10-Q · filed 2023-11-09 | $1.07M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $532.41K 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $1.60M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $439.50K 10-Q · filed 2022-11-10 | $844.98K derived: sum of 2 quarters · filed 2022-11-10 | $1.21M derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $405.48K 10-Q · filed 2022-11-10 | $771.39K derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | $365.91K 10-Q · filed 2022-11-10 | ||||
| 2020-12-31 | $742.03K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $194.88K 10-Q · filed 2021-11-10 | $381.74K derived: sum of 2 quarters · filed 2021-11-10 | $542.58K derived: sum of 3 quarters · filed 2021-11-10 | $660.11K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $186.86K 10-Q · filed 2021-11-10 | $347.70K derived: sum of 2 quarters · filed 2021-11-10 | $465.23K derived: sum of 3 quarters · filed 2021-11-10 | $600.62K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-03-31 | $160.84K 10-Q · filed 2021-11-10 | $278.37K derived: sum of 2 quarters · filed 2021-11-10 | $413.76K derived: sum of 3 quarters · filed 2021-11-10 | $525.11K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2019-12-31 | $117.53K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $252.92K derived: sum of 2 quarters · filed 2021-03-30 | $364.27K derived: sum of 3 quarters · filed 2021-03-30 | $462.24K 10-K · filed 2021-03-30 | |
| 2019-09-30 | $135.39K 10-Q · filed 2020-11-12 | $246.74K derived: sum of 2 quarters · filed 2020-11-12 | $344.71K 10-Q · filed 2019-11-12 | $425.52K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $111.35K 10-Q · filed 2020-11-12 | $209.32K 10-Q · filed 2019-08-14 | $290.13K derived: sum of 3 quarters · filed 2020-11-12 | $330.12K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-03-31 | $97.97K 10-Q · filed 2020-11-12 | $178.78K derived: sum of 2 quarters · filed 2020-11-12 | $218.77K derived: sum of 3 quarters · filed 2020-11-12 | $228.19K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2018-12-31 | $80.81K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $120.80K derived: sum of 2 quarters · filed 2020-03-27 | $130.22K derived: sum of 3 quarters · filed 2020-03-27 | $139.35K 10-K · filed 2020-03-27 | |
| 2018-09-30 | $39.99K 10-Q · filed 2019-11-12 | $49.41K derived: sum of 2 quarters · filed 2019-11-12 | $58.54K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $9.42K 10-Q · filed 2019-08-14 | $18.55K 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $9.12K 10-Q · filed 2019-05-14 | ||||
| 2017-12-31 | $15.83K 10-K · filed 2019-04-01 | ||||
| 2016-12-31 | $13.00 10-K · filed 2018-03-28 | $2.75M 10-K · filed 2017-03-31 | |||
| 2015-12-31 | $2.38M 10-K/A · filed 2017-06-13 | ||||
| 2014-12-31 | $885.00K 10-K/A · filed 2017-06-13 | ||||
| 2013-12-31 | $622.00K 10-K · filed 2016-03-10 | ||||
| 2012-12-31 | $529.00K 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |